Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase

European Heart Journal Advance Access published February 18, 2015.

Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. 

European Heart Journal (2017).

2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia.

European Heart Journal (2016).

2016 ESC/EAS Guidelines for the Management of Dyslipidaemias.

Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза.

Российские рекомендации VI пересмотр. Москва 2017 год.